HEROES Registry

Real world evaluation of ultrathin strut **Orsiro®** Biodegradable Polymer Sirolimus-eluting stent in STEMI patients

Conclusions

- At 1 year follow-up Orsiro showed excellent safety and efficacy with a cumulative incidence of DOCE of 3.7%.
- Event rates in the Heroes registry are comparable to the ones seen in the BIOSTEMI trial, confirming the results obtained in a large RCT.
- The HEROES Registry supports the real-world safety and efficacy of the Orsiro DES for STEMI patients undergoing primary PCI.

Study design

Observational, multicentre, retrospective registry evaluating the safety and the efficacy of Orsiro DES in STEMI patients undergoing primary PCI.

353 STEMI patients undergoing primary PCI with **Orsiro** DES in 9 centers in Italy

↓

12-month clinical follow-up

↓

36-month clinical follow-up

Endpoints

Primary endpoint
Device-Oriented Composite Endpoint (DOCE) of:
- Cardiac Death
- Target vessel Myocardial Infarction (TV-MI)
- Ischemia-driven Target Lesion Revascularization (TLR) at 12 months follow-up

Selected Secondary endpoints
- Individual components of the primary endpoint
- DOCE at 6 months and 3-year follow-up
- Any definite/probable Stent Thrombosis (ST)
- Any bleeding (in-hospital, within 7 days after pPCI and at follow-up)

Patient characteristics[1]

	Orsiro n = 353
Age (years)*	64.6 ± 11.8
Male	75.1%
Smoker	52.4%
Diabetes mellitus	21.5%
Hypertension	57.8%
Family history of CAD	25.5%
Previous PCI	9.9%
Previous CABG	2.0%

Lesion and Procedural Characteristics[1]

	Orsiro n = 353
Multivessel disease	53.3%
Bifurcation lesions	30.6%
Thrombectomy	42.2%
Baseline TIMI flow	
0-1	58.9%
2-3	41.1%
Thrombus grade	
0-2	67.7%
3-5	32.3%
Lesion length (mm)*	25.1 ± 14.5
Stents/lesion*	1.3 ± 0.6
Total stent length (mm)*	32.9 ± 16.4
Number of stents implanted	
1	69.1%
>1	30.9%
Mean stent diameter (mm)*	3.1 ± 0.4

* Data shown as mean ± SD

Primary Endpoint – DOCE up to 36 months



Selected Secondary Endpoints up to 36 months[1]

	Overall	0-6 months	6-12 months	12-36 months
Cardiac Death	4.8%	3.3%	0.0%	1.5%
TV-MI	1.2%	0.3%	0.3%	0.6%
TLR	1.2%	0.3%	0.3%	0.6%
ST	0.3%	0.3%	0.0%	0.0%
Bleeding	2.4%	0.0%	1.2%	1.2%

Principal investigator

Italo Porto, Hospital Policlinico San Martino, Genova, Italy

1. De Marzo et al. Hard Events AfteR Orsiro Sirolimus-Eluting Stent (HEROES) in STEMI: A Multicenter Registry. J Invasive Cardiol 2020.

Clinical data conducted with Orsiro, Orsiro Mission's predecessor device can be used to illustrate Orsiro Mission clinical outcomes. Orsiro and Orsiro Mission are trademarks or registered trademarks of the BIOTRONIK Group of Companies.

Jun_2021

BIOTRONIK AG
Ackerstrasse 6
8180 Bülach,
Switzerland

Tel +41 (0) 44 8645111
Fax +41 (0) 44 8645005
info.vi@biotronik.com
www.biotronik.com

BIOTRONIK
excellence for life